Literature DB >> 9718636

Patterns of current and lifetime substance use in schizophrenia.

I L Fowler1, V J Carr, N T Carter, T J Lewin.   

Abstract

A structured interview and standardized rating scales were used to assess a sample of 194 outpatients with schizophrenia in a regional Australian mental health service for substance use, abuse, and dependence. Case manager assessments and urine drug screens were also used to determine substance use. Additional measurements included demographic information, history of criminal charges, symptom self-reports, personal hopefulness, and social support. The sample was predominantly male and showed relative instability in accommodations, and almost half had a history of criminal offenses, most frequently drug or alcohol related. The 6-month and lifetime prevalence of substance abuse or dependence was 26.8 and 59.8 percent, respectively, with alcohol, cannabis, and amphetamines being the most commonly abused substances. Current users of alcohol comprised 77.3 percent and current users of other nonprescribed substances (excluding tobacco and caffeine) comprised 29.9 percent of the sample. Rates of tobacco and caffeine consumption were high. There was a moderate degree of concordance between case manager determinations of a substance-use problem and research diagnoses. Subjects with current or lifetime diagnoses of substance abuse/dependence were predominantly young, single males with higher rates of criminal charges; however, there was no evidence of increased rates of suicide attempts, hospital admissions, or daily doses of antipsychotic drugs in these groups compared with subjects with no past or current diagnosis of substance abuse or dependence. Subjects with a current diagnosis of substance use were younger at first treatment and currently more symptomatic than those with no past or current substance use diagnosis. The picture emerging from this study replicates the high rate of substance abuse in persons with schizophrenia reported in North American studies but differs from the latter in finding a slightly different pattern of substances abused (i.e., absence of cocaine), reflecting relative differences in the availability of certain drugs.

Entities:  

Mesh:

Year:  1998        PMID: 9718636     DOI: 10.1093/oxfordjournals.schbul.a033339

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  56 in total

1.  Perceived reasons for and consequences of substance abuse among patients with psychosis.

Authors:  Sahoo Saddichha; Ravi Prakash; Baxi N P Sinha; Christoday R J Khess
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status.

Authors:  Kate B Carey; Michael P Carey; Jeffrey S Simons
Journal:  J Nerv Ment Dis       Date:  2003-05       Impact factor: 2.254

3.  Illicit drug use in heavy smokers with and without schizophrenia.

Authors:  Kristen M Mackowick; Stephen J Heishman; Heidi J Wehring; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

Review 4.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 5.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 6.  Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review.

Authors:  Giuseppe Carrà; Sonia Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-13       Impact factor: 4.328

7.  Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia.

Authors:  Deanna L Kelly; Heather G Raley; Suzanne Lo; Katherine Wright; Fang Liu; Robert P McMahon; Eric T Moolchan; Stephanie Feldman; Charles M Richardson; Heidi J Wehring; Stephen J Heishman
Journal:  Schizophr Bull       Date:  2010-11-01       Impact factor: 9.306

8.  Effects of Δ-THC on Working Memory: Implications for Schizophrenia?

Authors:  Nehal P Vadhan; Mark R Serper; Margaret Haney
Journal:  Prim psychiatry       Date:  2009-01-01

9.  The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Authors:  Giuseppe Carrà; Sonia Johnson; Paul Bebbington; Matthias C Angermeyer; Dirk Heider; Traolach Brugha; Jean-Michel Azorin; Mondher Toumi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

10.  Demographic and clinical correlates of substance abuse comorbidity in schizophrenia.

Authors:  Tapas K Aich; Vinod K Sinha; Christoday R J Khess; Shailja Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.